Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

THERAVECTYS

Request full access

THERAVECTYS develops a platform for the prevention and treatment of cancers and other infectious diseases and conditions.

Paris, FranceFounded 2005Biotech & Life Sciences

About THERAVECTYS

Theravectys operates in the biotech sector, focusing on the development of T cell vaccines using a proprietary lentiviral vector platform. The company targets both prophylactic and therapeutic vaccines, addressing critical unmet medical needs such as chronic infections and cancers, including the global HIV epidemic. By leveraging over 20 years of research, Theravectys aims to transform the field of vaccinology through strategic industrial partnerships and collaborations, including a joint laboratory with the Pasteur Institute. The business model centers on preclinical proof of concept across a broad range of indications, moving products through clinical stages and regulatory approval. Revenue is generated through global licensing and partnerships, positioning Theravectys as a potential game-changer in global health.

Source: Dealroom company data

At a glance

Status
Operational
Employees
16
Open positions
None listed
Dealroom signal
69.0/100
Industry
Health
Sub-industry
BioTechnology
Sector
Tea, Wholesale, Intellectual Property, Biotechnology, Oncology, Immune System, Spinout, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VC✓Equity / VC Feb 2021 $18M $73M Undisclosed ↗
EARLY VC✓Equity / VC Jan 2015 $2.1M $8.4M Bpifrance —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

THERAVECTYS website traffic

Latest recorded traffic for THERAVECTYS is 2.3K monthly website visits, up 167.4% over the last three months. THERAVECTYS's team declined 15.8% over the past year.

Latest monthly visits2.3K 3-month web change+167.4% 1-year team growth-15.8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

THERAVECTYS in the Paris ecosystem

Live from Dealroom

The THERAVECTYS office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

Other known investors1 additional known investor

  • Institut Pasteur
Team profiled 14 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

See THERAVECTYS’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.